Thu, Aug 21, 2014, 9:55 AM EDT - U.S. Markets close in 6 hrs 5 mins


% | $
Quotes you view appear here for quick access.

Momenta Pharmaceuticals Inc. Message Board

  • t57776 t57776 Jan 25, 2012 5:05 AM Flag

    nvs 4th

    Sandoz net sales of USD 2.3 billion were down 5% (-4% cc) in the fourth quarter, impacted by additional competition to enoxaparin. Enoxaparin, our first generic blockbuster, achieved sales of USD 1.0 billion in 2011 (USD 225 million in the fourth quarter).

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • it'll be real interesting to see how different analysts apply their logic/knowledge of the formula of a possible new run rate of $900M-1.1B

      Oppenheimer has $16M as it's MNTA M-lov revenue.

      don't know what scenario/formula accounts for such low revenue.

      10 % of $160M?....crazy.

      • 1 Reply to t57776
      • I've given up trying to understand how these professional "analysts" model revenue for MNTA. With the new run rate of $900 M - $1.1 B in mLovenox sales, my Excel spreadsheet calculates a MNTA revenue at $260 M for 2012.

        Assumptions are as follows:
        Operating Margins at 68%
        NVS mLov revenue at $250 M/quarter

        Q1-2012 Profit Share 45% = $76.5M
        Q2-2012 Profit Share 45% = $76.5M
        Q3-2012 Profit Share 11% & 45% = [(135*0.11)+(170-135)*0.45] = $30.5M
        Q4-2012 Profit Share 45% = $76.5 M

11.30-0.03(-0.26%)9:55 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.